CL2021001039A1 - Conjugados de fármaco-anticuerpo que comprenden derivados de la ecteinascidina. - Google Patents
Conjugados de fármaco-anticuerpo que comprenden derivados de la ecteinascidina.Info
- Publication number
- CL2021001039A1 CL2021001039A1 CL2021001039A CL2021001039A CL2021001039A1 CL 2021001039 A1 CL2021001039 A1 CL 2021001039A1 CL 2021001039 A CL2021001039 A CL 2021001039A CL 2021001039 A CL2021001039 A CL 2021001039A CL 2021001039 A1 CL2021001039 A1 CL 2021001039A1
- Authority
- CL
- Chile
- Prior art keywords
- drug
- ecteinascidin
- derivatives
- antibody conjugates
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382759 | 2018-10-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001039A1 true CL2021001039A1 (es) | 2021-10-01 |
Family
ID=64426824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001039A CL2021001039A1 (es) | 2018-10-25 | 2021-04-22 | Conjugados de fármaco-anticuerpo que comprenden derivados de la ecteinascidina. |
Country Status (37)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102491180B1 (ko) * | 2017-04-27 | 2023-01-20 | 파르마 마르 에스.에이. | 항종양 화합물 |
| WO2021218896A1 (zh) * | 2020-04-26 | 2021-11-04 | 江苏恒瑞医药股份有限公司 | 海鞘素类衍生物及其制备方法与医药用途 |
| US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
| IL308389A (en) * | 2021-05-19 | 2024-01-01 | Pharma Mar Sa | Dosing regimens for acubactadine |
| KR102625740B1 (ko) * | 2021-07-15 | 2024-01-17 | 주식회사 새한비엠 | 폐수지 재료 및 미네랄 바인더를 이용한 단열차음재의 제조 방법 및 그 단열차음재 |
| WO2024091437A1 (en) * | 2022-10-25 | 2024-05-02 | Merck Sharp & Dohme Llc | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof |
| AU2024210894A1 (en) * | 2023-01-17 | 2025-07-17 | Adcytherix Sas | Ecteinascidin derivative antibody drug conjugates |
| WO2024186263A1 (en) | 2023-03-07 | 2024-09-12 | Axcynsis Therapeutics Pte. Ltd. | Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives |
| CN118878690B (zh) * | 2023-11-28 | 2026-01-09 | 南京大学 | 一种抗地高辛纳米抗体的制备及其应用 |
| TW202547489A (zh) * | 2024-04-30 | 2025-12-16 | 西班牙商瑪製藥股份有限公司 | 化合物ia於包括與阿替利珠單抗的組合療法之癌症的治療中之用途 |
| TW202547488A (zh) * | 2024-04-30 | 2025-12-16 | 西班牙商瑪製藥股份有限公司 | 於癌症的治療中之化合物Ｉａ和拓樸異構酶Ｉ抑制劑的組合 |
| WO2025233522A1 (en) * | 2024-05-10 | 2025-11-13 | Pharma Mar, S.A. | Synthetic process for an ecteinascidin |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| AR035842A1 (es) | 1999-05-14 | 2004-07-21 | Pharma Mar Sa | Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo |
| GB0119243D0 (en) | 2001-08-07 | 2001-10-03 | Pharma Mar Sa | Antitumoral analogs of ET-743 |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| KR20070053214A (ko) * | 2004-08-26 | 2007-05-23 | 니콜라스 피라말 인디아 리미티드 | 신규 생분해성 링커를 함유하는 프로드럭 |
| JP4993645B2 (ja) | 2004-12-01 | 2012-08-08 | ジェネンテック， インコーポレイテッド | 抗体薬剤結合体および方法 |
| CA3000520C (en) | 2005-08-24 | 2023-04-04 | Immunogen, Inc. | Process for preparing antibody maytansinoid conjugates |
| GB201309807D0 (en) * | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
| GB201506405D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| KR102491180B1 (ko) * | 2017-04-27 | 2023-01-20 | 파르마 마르 에스.에이. | 항종양 화합물 |
| CN115427081B (zh) * | 2020-04-21 | 2025-12-09 | 法马马有限公司 | 药物抗体共轭物 |
-
2019
- 2019-10-23 TW TW108138205A patent/TWI824043B/zh active
- 2019-10-24 AR ARP190103069A patent/AR117657A1/es unknown
- 2019-10-25 RS RS20230219A patent/RS64068B1/sr unknown
- 2019-10-25 ES ES19790550T patent/ES2939494T3/es active Active
- 2019-10-25 HR HRP20230275TT patent/HRP20230275T1/hr unknown
- 2019-10-25 MY MYPI2021002234A patent/MY206221A/en unknown
- 2019-10-25 UA UAA202102699A patent/UA129803C2/uk unknown
- 2019-10-25 DK DK19790550.8T patent/DK3870234T3/da active
- 2019-10-25 LT LTEPPCT/EP2019/079188T patent/LT3870234T/lt unknown
- 2019-10-25 WO PCT/EP2019/079188 patent/WO2020084115A1/en not_active Ceased
- 2019-10-25 PL PL19790550.8T patent/PL3870234T3/pl unknown
- 2019-10-25 SM SM20230076T patent/SMT202300076T1/it unknown
- 2019-10-25 CN CN201980084790.7A patent/CN113226377B/zh active Active
- 2019-10-25 SG SG11202104154WA patent/SG11202104154WA/en unknown
- 2019-10-25 IL IL282577A patent/IL282577B2/en unknown
- 2019-10-25 HU HUE19790550A patent/HUE061606T2/hu unknown
- 2019-10-25 FI FIEP19790550.8T patent/FI3870234T3/fi active
- 2019-10-25 AU AU2019368687A patent/AU2019368687B2/en active Active
- 2019-10-25 EP EP19790550.8A patent/EP3870234B1/en active Active
- 2019-10-25 MA MA59661A patent/MA59661B1/fr unknown
- 2019-10-25 SI SI201930466T patent/SI3870234T1/sl unknown
- 2019-10-25 PT PT197905508T patent/PT3870234T/pt unknown
- 2019-10-25 US US17/288,567 patent/US20230012681A1/en active Pending
- 2019-10-25 EA EA202191131A patent/EA202191131A1/ru unknown
- 2019-10-25 CA CA3117268A patent/CA3117268C/en active Active
- 2019-10-25 KR KR1020217015900A patent/KR20210086669A/ko active Pending
- 2019-10-25 MD MDE20210819T patent/MD3870234T2/ro unknown
- 2019-10-25 BR BR112021007718-9A patent/BR112021007718A2/pt unknown
- 2019-10-25 JP JP2021523064A patent/JP7629400B2/ja active Active
- 2019-10-25 MX MX2021004746A patent/MX2021004746A/es unknown
-
2021
- 2021-04-22 CL CL2021001039A patent/CL2021001039A1/es unknown
- 2021-04-23 PH PH12021550930A patent/PH12021550930A1/en unknown
- 2021-04-25 JO JOJO/P/2021/0083A patent/JOP20210083B1/ar active
- 2021-04-25 SA SA521421855A patent/SA521421855B1/ar unknown
- 2021-05-20 EC ECSENADI202135414A patent/ECSP21035414A/es unknown
- 2021-05-21 ZA ZA2021/03478A patent/ZA202103478B/en unknown
- 2021-05-24 CO CONC2021/0006838A patent/CO2021006838A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001039A1 (es) | Conjugados de fármaco-anticuerpo que comprenden derivados de la ecteinascidina. | |
| CL2019001077A1 (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer. | |
| MX2023001648A (es) | Conjugado de anticuerpo y farmaco. | |
| UY39906A (es) | Derivados de 1,4-oxazepano y usos de los mismos | |
| CY1124404T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 και μεθοδοι χρησης αυτων | |
| PE20181292A1 (es) | Conjugados anticuerpo anti-dll3-farmaco y metodos de uso | |
| MX2019008698A (es) | Derivado de piridina como inhibidor de ask1 y metodo de preparacion y uso del mismo. | |
| MX2018011627A (es) | Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles. | |
| PE20191235A1 (es) | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente | |
| GEP20247627B (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| BR112022020324A2 (pt) | Derivados de diamina macrocíclica como inibidores de ent para o tratamento de cânceres e combinação dos mesmos com antagonistas de receptor de adenosina | |
| MX375383B (es) | Conjugados de anticuerpo-fármaco e inmunotoxinas. | |
| EA201992320A1 (ru) | Пиперидины в качестве ковалентных ингибиторов менина | |
| ECSP17007208A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| MX2021009439A (es) | Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7. | |
| AR100431A1 (es) | Compuestos de pladienolida piridina y métodos de uso | |
| MX2021011118A (es) | Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2. | |
| NI200900183A (es) | Compuestos de pirido [2,3-d] pirimidina - 7 - ona como inhibidores de pi3k - alfa para el tratamiento del cáncer. | |
| MX2018009870A (es) | Inhibidores de taf1 para la terapia del cancer. | |
| MX2019011743A (es) | Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres. | |
| DOP2022000224A (es) | Conjugados de anticuerpos de fármacos | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| CL2019002527A1 (es) | Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer. | |
| CY1121693T1 (el) | Θετικοι αλλοστερικοι διαμορφωτες μουσκαρινικου υποδοχεα μ1 | |
| CO2021001925A2 (es) | Piridopirimidinas como inhibidores del receptor de histamina h4 |